A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Sotagliflozin belongs to a class of medications called gliflozins that help lower blood sugar levels by preventing the ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.

Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...

– Initiating Phase 2 trial to evaluate lorundrostat for the treatment of patients with moderate-to-severe obstructive sleep apnea (OSA) and hypertension – ...

SGLT-2 inhibitors canagliflozin, empagliflozin, and dapagliflozin showed overall comparable effectiveness on cardiovascular outcomes in T2D.

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio ...

" Empagliflozin significantly reduced CI-AKI incidence in PCI patients by enhancing renal function markers, including eGFR ...

Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.